Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
JCI Insight. 2020 Sep 3;5(17):e140532. doi: 10.1172/jci.insight.140532.
JCI Insight. 2020.
PMID: 32730231
Free PMC article.